<--- Back to Details
First PageDocument Content
Bevacizumab / Clinical trial / Radiation Therapy Oncology Group / Neuroblastoma / Oncology / Cancer and Leukemia Group B / Yale Cancer Center / Medicine / Cancer organizations / Cancer Trials Support Unit
Date: 2012-03-07 11:05:07
Bevacizumab
Clinical trial
Radiation Therapy Oncology Group
Neuroblastoma
Oncology
Cancer and Leukemia Group B
Yale Cancer Center
Medicine
Cancer organizations
Cancer Trials Support Unit

Microsoft PowerPoint - Abrams.ppt [Compatibility Mode]

Add to Reading List

Source URL: deainfo.nci.nih.gov

Download Document from Source Website

File Size: 1,69 MB

Share Document on Facebook

Similar Documents

1. Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 1993;169:.

1. Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 1993;169:.

DocID: 1ukO2 - View Document

Numeric	
  Key	
  of	
  Factor	
  levels	
  for	
  extraction	
  parameters	
  	
   Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review Marianne Isabelle Martic-Kehl,

Numeric  Key  of  Factor  levels  for  extraction  parameters     Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review Marianne Isabelle Martic-Kehl,

DocID: 1qWRv - View Document

ANTI-TROPOMYOSIN AGENTS ENHANCE THE ANTITUMOR EFFECTIVENESS OF MICROTUBULE INHIBITORS IN PRECLINICAL MODELS OF NEUROBLASTOMA. JUSTINE STEHN1,2, MARK CURRIER3, DUO CHEN3, BROOKE NARTKER3, ELEANOR EIFFE1, ANDREW HEATON1,2,

ANTI-TROPOMYOSIN AGENTS ENHANCE THE ANTITUMOR EFFECTIVENESS OF MICROTUBULE INHIBITORS IN PRECLINICAL MODELS OF NEUROBLASTOMA. JUSTINE STEHN1,2, MARK CURRIER3, DUO CHEN3, BROOKE NARTKER3, ELEANOR EIFFE1, ANDREW HEATON1,2,

DocID: 1qUPq - View Document

www.edoriumjournals.com  CASE REPORT PEER REVIEWED | OPEN ACCESS

www.edoriumjournals.com CASE REPORT PEER REVIEWED | OPEN ACCESS

DocID: 1qNSk - View Document

May 2016 29th April, 2015 INVESTOR FACT SHEET Business Summary Novogen is a drug development company focused on

May 2016 29th April, 2015 INVESTOR FACT SHEET Business Summary Novogen is a drug development company focused on

DocID: 1qNjw - View Document